All In Biotech

NDA 021529 · Organon

Implanon

Etonogestrel · Implantation · Progestin

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jul 17, 2006

Approved uses

3

Original approval plus efficacy supplements

Registered trials

90

14 Phase 3, 5 recruiting

FAERS reports

57,570

13,734 serious, 110 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION and REMOVAL Improper insertion of NEXPLANON increases the risk of complications [see Warnings and Precautions (5.1) ] . Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion [see Warnings and Precautions (5.1) ] . Because of the risk of complications due to improper insertion and removal NEXPLANON is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the NEXPLANON REMS [see Warnings and Precautions (5.2) ] . WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION and REMOVAL Improper insertion of NEXPLANON increases the risk of complications [see Warnings and Precautions (5.1) ] . Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion [see Warnings and Precautions (5.1) ] ....

What it is approved for

From the label in effect May 28, 2026.

NEXPLANON ® is indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. NEXPLANON is a progestin indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. ( 1 )

Mechanism: The contraceptive effect of NEXPLANON is achieved by suppression of ovulation, increased viscosity of the cervical mucus, and alterations in the endometrium.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • IMPLANON · ETONOGESTREL 68MG/IMPLANT · IMPLANT, IMPLANTATION · Discontinued
  • NEXPLANON · ETONOGESTREL 68MG/IMPLANT · IMPLANT, IMPLANTATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Etonogestrel" as an intervention, any sponsor and status, largest first.

All 90 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event12,139
  • product quality issue6,915
  • complication associated with device6,622
  • device breakage5,381
  • incorrect product administration duration5,033
  • complication of device insertion4,758
  • device difficult to use4,584
  • complication of device removal4,373
  • unintended pregnancy3,743
  • device deployment issue3,686
  • pregnancy with implant contraceptive3,434
  • vaginal haemorrhage3,434

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
200634
200788
200856
200956
20103
201155
2012619
20132,766
20143,778
20154,243
20164,828
20174,427
20184,941
20194,845
20203,976
20213,817
20223,505
20231,626
20241,477
20251,819
202610,610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nexplanon (Etonogestrel)

2024 spending

$455K

Beneficiaries

392

393 claims

Per beneficiary

$1,162

$1,158.73 per unit

View as table
YearSpending
2020$0
2021$66,788
2022$273,157
2023$401,524
2024$455,380

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 188 on PubMed

Sponsor: Organon · Also marketed as Nexplanon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.